S&P 500
(0.11%) 5 254.35 points
Dow J
(0.12%) 39 807 points
Nasdaq
(-0.12%) 16 379 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(1.45%) $922.85
USD/EUR
(0.06%) $0.927
USD/NOK
(0.24%) $10.87
USD/GBP
(-0.05%) $0.792
USD/RUB
(-0.03%) $92.55

Realtime updates for vTv Therapeutics Inc [VTVT]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Last Updated28 Mar 2024 @ 16:00

-1.13% $ 23.53

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302
Profile picture for vTv Therapeutics Inc

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis...

Stats
Today's Volume 13 672.00
Average Volume 79 378.00
Market Cap 57.25M
EPS $0 ( 2024-03-11 )
Next earnings date ( $0 ) 2024-05-09
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -2.42
ATR14 $0.461 (1.93%)
Insider Trading
Date Person Action Amount type
2024-03-13 Phillips Anne M. Buy 0
2024-03-05 Baker Bros. Advisors Lp Buy 52 925 Prefunded Warrants
2024-03-05 Baker Bros. Advisors Lp Buy 4 780 Prefunded Warrants
2024-03-05 Baker Bros. Advisors Lp Sell 52 881 Common Stock
2024-03-05 Baker Bros. Advisors Lp Sell 4 776 Common Stock
INSIDER POWER
54.96
Last 83 transactions
Buy: 13 416 272 | Sell: 2 785 487

Volume Correlation

Long: -0.16 (neutral)
Short: -0.41 (neutral)
Signal:(55.15) Neutral

vTv Therapeutics Inc Correlation

10 Most Positive Correlations
SIFY0.816
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

vTv Therapeutics Inc Correlation - Currency/Commodity

The country flag 0.58
( weak )
The country flag 0.60
( weak )
The country flag 0.23
( neutral )
The country flag -0.08
( neutral )
The country flag 0.21
( neutral )
The country flag 0.66
( moderate )

vTv Therapeutics Inc Financials

Annual 2023
Revenue: $0
Gross Profit: $-90 000.00 (0.00 %)
EPS: $-9.71
Q4 2023
Revenue: $0
Gross Profit: $-23 000.00 (0.00 %)
EPS: $-1.670
Q3 2023
Revenue: $0
Gross Profit: $-22 000.00 (0.00 %)
EPS: $-0.0817
Q2 2023
Revenue: $9 000.00
Gross Profit: $-14 000.00 (-155.56 %)
EPS: $-0.0690

Financial Reports:

No articles found.

vTv Therapeutics Inc

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators